To validate the critical role of CCL2 in controlling the migration ability of DT-treated prostate cancer cells, we investigated the effects of DT or combined treatment with IR (5 μM DT plus 5 Gy IR) and with or without CCL2 on the migration ability of prostate cancer cells. This evidence concerns the gene CCL2 and prostate carcinoma.